Related Experiment Video
Updated: May 3, 2026

A Neonatal BALB/c Mouse Model of Necrotizing Enterocolitis
Published on: November 30, 2021
Lactoferrin and necrotizing enterocolitis
Michael P Sherman1, Mindy M Miller, Jan Sherman
1aDepartment of Child Health bDepartment of Molecular Microbiology and Immunology, School of Medicine cSinclair School of Nursing, University of Missouri, Columbia, Missouri dDivision of Neonatal Medicine, Nemours Children's Hospital, Orlando, Florida, USA.
Insights
Enteral lactoferrin may reduce necrotizing enterocolitis in preterm infants. Breast milk, a natural lactoferrin source, is recommended for extremely preterm infants to potentially lower disease incidence.
Area of Science:
- Neonatal Medicine
- Gastroenterology
- Immunology
Background:
- Necrotizing enterocolitis (NEC) is a severe gastrointestinal disease in preterm infants.
- Lactoferrin, a protein found in milk, has demonstrated protective properties.
Purpose of the Study:
- To review the scientific and clinical evidence on the efficacy of enteral lactoferrin in preventing NEC in preterm infants.
- To assess the potential of lactoferrin as a therapeutic agent for NEC.
Main Methods:
- Review of preclinical studies in neonatal rats.
- Analysis of a multicentered clinical trial involving very low-birth weight preterm infants.
Main Results:
- Oral lactoferrin reduced bacteremia and mortality in rat models of NEC.
- Enteral bovine lactoferrin significantly reduced late-onset sepsis in preterm infants.
- A trend towards diminished NEC incidence was observed in the clinical trial.
Conclusions:
- Colostrum, rich in lactoferrin, should be given to extremely preterm infants immediately after birth.
- Continued breastfeeding throughout hospitalization is recommended.
- Further research is needed to confirm the reduction in NEC prevalence with these practices.
Purpose Of Review:
There is an intense interest among neonatal caregivers as to whether lactoferrin given enterally may reduce the incidence of necrotizing enterocolitis in preterm infants. This review presents scientific and clinical evidence that lactoferrin alleviates or prevents this life-threatening disease.
Recent Findings:
Preclinical studies in neonatal rats showed that lactoferrin given orally before enteral infection with pathogenic Escherichia coli reduced bacteremia and mortality. A multicentered clinical trial found that very low-birth weight preterm infants given bovine lactoferrin had a significant reduction in late-onset sepsis; there was also a trend towards a diminished incidence of necrotizing enterocolitis. Although multicentered trials of lactoferrin use in preterm infants are near completion, regulatory burdens required to bring lactoferrin to the bedside may limit its availability.
Summary:
Extremely preterm infants should receive colostrum, a natural lactoferrin concentrate, immediately after birth and, ideally, continue on breast milk throughout the hospital stay. This practice appears well tolerated, but additional experience will tell us whether this practice reduces the prevalence of necrotizing enterocolitis.
Related Concept Videos
Bacterial Gastroenteritis
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Bacterial Toxins
Cellular Injury IV: Necrosis
Inducible Operons: lac Operon

